Jefferies Group’s ImmunityBio IBRX Stock Holding History

Jefferies Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-54,700	Closed	-$627K	–	2402
2015 Q3	$627K	Buy	+54,700	New	+$1.19M	﹤0.01%	1411

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jefferies Group's IBRX Position: Q1 2019 in Review

Jefferies Group sold out of ImmunityBio (IBRX) in Q1 2019, closing a stake of 41,881 shares — an estimated $49K sold.

Jefferies Group first reported a position in IBRX in Q3 2015 and held it in 2 quarters. The position peaked at $561K in Q3 2015. 58 funds tracked by Wall St. Rank hold IBRX as of Q1 2019.

Jefferies Group reported no remaining ImmunityBio position as of Q1 2019 after selling out during the quarter.
Jefferies Group sold 41,881 ImmunityBio shares in Q1 2019, an estimated $49K.
Jefferies Group first reported a position in ImmunityBio in Q3 2015 and held it in 2 quarters.
Jefferies Group's ImmunityBio position peaked at $561K in Q3 2015.
58 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2019.

Based on Jefferies Group's 13F filing for Q1 2019, filed 15 May 2019.